Press & news - FluoGuide A/S

Start » Press & news

2023

29 November, 2023 FluoGuide A/S publishes interim report for the period January – September 2023 News English Regulatory Listing Regulation Report Interim Q3 IR

Copenhagen, Denmark, 29 November 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its...

13 November, 2023 FluoGuide announces FG001 meets primary endpoint in phase llb trial in aggressive brain cancer News Corporate Action Other English Regulatory MAR IR

Copenhagen, Denmark – FluoGuide A/S (“FluoGuide” or the “Company”), a pioneer in the cutting-edge field...

6 November, 2023 FluoGuide confirms positive topline results from phase lla trial of FG001 in head & neck cancer at International Academy of Oral Oncology conference News Corporate Action Other English IR

Copenhagen, Denmark – FluoGuide A/S (“FluoGuide” or the “Company”), a pioneer in the cutting-edge field...

3 October, 2023 FluoGuide receives FDA Orphan Drug Designation for FG001 in high-grade glioma News Corporate Action Other English Regulatory MAR IR

Copenhagen, Denmark – FluoGuide A/S (OMX: FLUO “FluoGuide” or the “Company”), a pioneer in the cutting-edge...

8 September, 2023 FluoGuide receives Danish award for the best share price performance since IPO News Corporate Action Other English IR

Copenhagen, Denmark, 8 September 2023 – FluoGuide A/S (“FluoGuide” or the “Company”), a pioneer in the...

7 September, 2023 Positive interim data from phase lla trial of FG001 in head & neck cancer presented as a case report at the World Molecular Imaging Congress in Prague News Corporate Action Other English IR

Copenhagen, Denmark, 7 September 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to see...

30 August, 2023 FluoGuide A/S publishes interim report for the period January – June 2023 News English Regulatory Listing Regulation Report Interim Q2 IR

Copenhagen, Denmark, 30 August 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its...

29 August, 2023 FluoGuide reports further positive interim data from phase IIa trial of FG001 in head & neck cancer News Corporate Action Other English Regulatory MAR IR

Copenhagen, Denmark – FluoGuide A/S (“FluoGuide” or the “Company”), a pioneer in the cutting-edge field...

28 August, 2023 FluoGuide completes patient enrollment and treatment in FG001 phase llb clinical trial in aggressive brain cancer News Corporate Information Other Corporate Information English IR

Copenhagen, Denmark – FluoGuide A/S (“FluoGuide” or the “Company”), a pioneer in the cutting-edge field...

2023

Calendar &upcoming reports

Calendar &
upcoming reports